Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-015212
Filing Date
2023-05-03
Accepted
2023-05-03 16:07:02
Documents
78
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ardx-20230331.htm   iXBRL 10-Q 1589130
2 EX-31.1 ardx-20230331xex311.htm EX-31.1 9855
3 EX-31.2 ardx-20230331xex312.htm EX-31.2 9877
4 EX-32.1 ardx-20230331xex321.htm EX-32.1 6551
10 ardx-20230331_g1.jpg GRAPHIC 75659
  Complete submission text file 0001628280-23-015212.txt   7269722

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ardx-20230331.xsd EX-101.SCH 55533
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ardx-20230331_cal.xml EX-101.CAL 66610
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ardx-20230331_def.xml EX-101.DEF 232191
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ardx-20230331_lab.xml EX-101.LAB 639430
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ardx-20230331_pre.xml EX-101.PRE 400818
72 EXTRACTED XBRL INSTANCE DOCUMENT ardx-20230331_htm.xml XML 1062591
Mailing Address 34175 ARDENWOOD BLVD. FREMONT CA 94555
Business Address 34175 ARDENWOOD BLVD. FREMONT CA 94555 510-745-7047
ARDELYX, INC. (Filer) CIK: 0001437402 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36485 | Film No.: 23883711
SIC: 2834 Pharmaceutical Preparations